Table 3.
Rates of infectious disease testing before and after exposure
| HCV | HIV | HBV | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Pre. | Exp. | Diff. | Pre. | Exp. | Diff. | Pre. | Exp. | Diff. | |
| Unadjusted notification effect | |||||||||
| Exposure | 8.8% | 83.2% | 74.4 | 3.8% | 82.8% | 79.0 | 5.6% | 82.9% | 77.3 |
| Control | 6.8% | 8.6% | 1.8 | 2.3% | 4.9% | 2.6 | 4.5% | 5.4% | 1.0 |
| Difference | 2.0 | 74.6 | 72.6** | 1.6 | 77.9 | 76.3** | 1.1 | 77.4 | 76.3** |
| Adjusted notification effect | |||||||||
| Marginal effect (percentage points) | 73.2** | 76.8** | 77.1** | ||||||
| Overall AOR (95% CI) | 49.7 (41.2 to 60.0)** | 103.8 (78.1 to 137.9)** | 88.4 (70.4 to 111.0)** | ||||||
| African–American AOR (95% CI) | 0.74 (0.61 to 0.89)* | 0.46 (0.37 to 0.56)** | 0.66 (0.54 to 0.81)** | ||||||
| Marginal effect for African–American patients† | −5.0* | −14.1** | −6.6** | ||||||
Models control for patient-level clustering.
*p<0.001; **p<0.0001.
†Marginal effects represent the predicted percentage point difference between African-American and white Veterans at the means of the other covariates.
AOR, adjusted ORs; HBV, hepatitis B virus; HCV, hepatitis C virus.